Seebri Breezhaler Inhaler contains glycopyrronium, a long-acting muscarinic antagonist (LAMA) used in the maintenance treatment of chronic obstructive pulmonary disease (COPD). It works by relaxing and widening the airways in the lungs, making it easier to breathe and reducing symptoms such as breathlessness, coughing, and wheezing.

Unlike reliever inhalers, Seebri Breezhaler is not designed for immediate relief but for regular, once-daily use to help manage COPD symptoms over time. The inhaler delivers a measured dose of dry powder through the Breezhaler device, ensuring effective lung delivery. This helps improve lung function, reduce flare-ups, and support better daily breathing.